Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.

Abstract: Disclosed are compounds of Formula (I): or pharmaceutically acceptable salts or solvates thereof, wherein R1, R3, X, Y, Z, and W are as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a proliferative disease, such as cancer.

Abstract: A data dictionary generation system automatically populates and updates a data dictionary for listings offering shared data. A data dictionary includes metadata describing the shared data, including the individual objects, such as the individual tables, schemas, views, and functions. The shared data and each individual data object may be described in the data dictionary by a set of data fields that corresponds to the shared dataset or the object type of the individual object. The data dictionary can be presented to data consumers along with the description of the listing to provide data consumers with a comprehensive description of the shared data provided by a listing, including a high-level summary of the shared data and description of each individual object included in the shared data. The data dictionary allows data consumers to understand the contents of the shared data and how to use the shared data.

Abstract: Disclosed are compounds of Formula (I): or pharmaceutically acceptable salts or solvates thereof, wherein R1, R3, X, Y, Z, and W are as defined herein. The compounds are, for example, inhibitors of WRN helicase and useful in treating a proliferative disease, such as cancer.

Abstract: In at least a medical system including a structure, a plurality of transducers located on the structure, a shaft member configured to percutaneously deliver the structure to a location within a patient, a plurality of conductors at least partially within the shaft member and coupled to the transducers, and a controller operatively coupled to the transducers via the conductors, the controller may cause first electrical power to be delivered to one or more of the transducers for a first period of time, where second electrical power less than the first electrical power, if delivered for a second period of time longer than the first period time would result in a steady-state temperature of a portion of the shaft member that would be just below a safe temperature limit for at least the portion of the shaft member.

Abstract: A friction material has a first outermost surface and a second outermost surface spaced apart from the first outermost surface. The friction material includes a base which forms at least a portion of the first outermost surface. The base includes fibers present in an amount of from 20 to 80 weight percent, a filler present in an amount of from 20 to 80 weight percent, and a deposit which forms at least a portion of the second outermost surface and includes a friction adjusting agent. The friction material further includes a resin disposed throughout the friction material. The deposit is disposed in the friction material in a gradated pattern. At least a portion of the deposit is exposed to the environment and the second outermost surface has a surface roughness of from 2 to 11 micrometers as determined by non-contact laser measurement according to ISO 25178.

Abstract: A friction material presents a friction generating surface and a bonding surface facing opposite said friction generating surface. The friction material includes structural fibers, friction particles, polyvinyl alcohol fibers, and a resin. A method of forming the friction material is also disclosed. The method comprises the steps of: combining the structural fibers, the friction particles, and the polyvinyl alcohol fibers having an average diameter of less than about 11 ?m, an average length of less than about 4 mm, an average denier of less than about 1, to form a substrate material; impregnating the substrate material with the resin; and curing the resin to form the friction material.

Abstract: A friction material includes a base, a deposit including a friction modifier, and a resin disposed throughout the friction material. The base includes aramid fibers present in an amount of from greater than 50 weight percent to 70 weight percent, based on a total weight of the base. The base also includes a filler present in an amount from 30 weight percent to less than 50 weight percent, based on a total weight of the base. The friction material is also free of a material having a thermal degradation temperature of less than 200° C. The friction material may have a porosity of from 60% to 85% as determined using ASTM D4404-10 and a median pore size of from 0.5 ?m to 50 ?m, as determined using ASTM D4404-10.

Abstract: The present invention provides various functionalized nanodiamond particles. In particular, the present invention provides soluble complexes of nanodiamond particles and therapeutic agents, for example insoluble therapeutics, anthracycline and/or tetracycline compounds, nucleic acids, proteins, etc. The present invention also provides materials and devices for the controlled release of therapeutics, and methods for uses thereof.

Abstract: A friction material has a first outermost surface and a second outermost surface spaced apart from the first outermost surface. The friction material includes a base which forms at least a portion of the first outermost surface. The base includes fibers present in an amount of from 20 to 80 weight percent, a filler present in an amount of from 20 to 80 weight percent, and a deposit which forms at least a portion of the second outermost surface and includes a friction adjusting agent. The friction material further includes a resin disposed throughout the friction material. The deposit is disposed in the friction material in a gradated pattern. At least a portion of the deposit is exposed to the environment and the second outermost surface has a surface roughness of from 2 to 11 micrometers as determined by non-contact laser measurement according to ISO 25178.

Abstract: A friction material presents a friction generating surface and a bonding surface facing opposite said friction generating surface. The friction material includes structural fibers, friction particles, polyvinyl alcohol fibers, and a resin. A method of forming the friction material is also disclosed. The method comprises the steps of: combining the structural fibers, the friction particles, and the polyvinyl alcohol fibers having an average diameter of less than about 11 ?m, an average length of less than about 4 mm, an average denier of less than about 1, to form a substrate material; impregnating the substrate material with the resin; and curing the resin to form the friction material.

Abstract: A friction material includes a base, a deposit including a friction modifier, and a resin disposed throughout the friction material. The base includes aramid fibers present in an amount of from greater than 50 weight percent to 70 weight percent, based on a total weight of the base. The base also includes a filler present in an amount from 30 weight percent to less than 50 weight percent, based on a total weight of the base. The friction material is also free of a material having a thermal degradation temperature of less than 200° C. The friction material may have a porosity of from 60% to 85% as determined using ASTM D4404-10 and a median pore size of from 0.5 ?m to 50 ?m, as determined using ASTM D4404-10.

Abstract: The present invention provides various functionalized nanodiamond particles. In particular, the present invention provides soluble complexes of nanodiamond particles and therapeutic agents, for example insoluble therapeutics, anthracycline and/or tetracycline compounds, nucleic acids, proteins, etc. The present invention also provides materials and devices for the controlled release of therapeutics, and methods for uses thereof.

Abstract: One embodiment of the invention may include a product comprising: a friction material comprising a plurality of fibers having a fiber diameter ranging from about 1 to about 20 micrometers, the fibers comprising ceramic or mineral fibers and reinforcing fibers to add strength, the reinforcing fibers being fibrillated with a Canadian Standard Freeness greater than 300.

Abstract: A crystallization chip has a two-dimensional substrate surface with modified wetting properties convenient for the evaluation of the crystallization experiment results by optical microscope and by X-ray diffraction. A crystallization chip mount comprises a base and a support structure that is connected to the base. The support structure provides a first channel that receives a portion of the crystallization chip. A crystallization chip holder comprises a body defining at least one slot to slidably receive the crystallization chip described herein. The at least one slot extends from an upper surface to a lower surface of the body. The crystallization chip holder further includes at least one support surface for each slot. For a given slot the at least one support surface is disposed on an edge of at least two surfaces of portions of the body that define the given slot. During use, the at least one support surface supports the crystallization chip prior to, during or after the formation of crystals.

Abstract: The present invention provides various functionalized nanodiamond particles. In particular, the present invention provides soluble complexes of nanodiamond particles and therapeutic agents, for example insoluble therapeutics, anthracycline and/or tetracycline compounds, nucleic acids, proteins, etc.

Abstract: A system and apparatus for moving and packaging oriented containers through an application machine and to a container carrier wherein a plurality of containers are fed in a desired rotational position prior to a transfer turret and gripped as the transfer turret rotationally transfers the oriented container to the container carrier.

Abstract: The present invention provides materials and devices for the controlled release of therapeutics, and methods for uses thereof.